These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26515728)

  • 21. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
    Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
    Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer.
    Obradovic AZ; Dallos MC; Zahurak ML; Partin AW; Schaeffer EM; Ross AE; Allaf ME; Nirschl TR; Liu D; Chapman CG; O'Neal T; Cao H; Durham JN; Guner G; Baena-Del Valle JA; Ertunc O; De Marzo AM; Antonarakis ES; Drake CG
    Clin Cancer Res; 2020 Jul; 26(13):3182-3192. PubMed ID: 32173650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice.
    Smith JP; Wang S; Nadella S; Jablonski SA; Weiner LM
    Cancer Immunol Immunother; 2018 Feb; 67(2):195-207. PubMed ID: 29043413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses.
    Garbe AI; Vermeer B; Gamrekelashvili J; von Wasielewski R; Greten FR; Westendorf AM; Buer J; Schmid RM; Manns MP; Korangy F; Greten TF
    Cancer Res; 2006 Jan; 66(1):508-16. PubMed ID: 16397267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.
    De Remigis A; de Gruijl TD; Uram JN; Tzou SC; Iwama S; Talor MV; Armstrong TD; Santegoets SJ; Slovin SF; Zheng L; Laheru DA; Jaffee EM; Gerritsen WR; van den Eertwegh AJ; Le DT; Caturegli P
    Int J Cancer; 2015 Jan; 136(1):127-37. PubMed ID: 24832153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralizing TGF-β promotes anti-tumor immunity of dendritic cells against pancreatic cancer by regulating T lymphocytes.
    Pu N; Zhao G; Gao S; Cui Y; Xu Y; Lv Y; Nuerxiati A; Wu W
    Cent Eur J Immunol; 2018; 43(2):123-131. PubMed ID: 30135623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B cell-Derived IL35 Drives STAT3-Dependent CD8
    Mirlekar B; Michaud D; Lee SJ; Kren NP; Harris C; Greene K; Goldman EC; Gupta GP; Fields RC; Hawkins WG; DeNardo DG; Rashid NU; Yeh JJ; McRee AJ; Vincent BG; Vignali DAA; Pylayeva-Gupta Y
    Cancer Immunol Res; 2020 Mar; 8(3):292-308. PubMed ID: 32024640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
    Blair AB; Zheng L
    Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TAp73 loss favors Smad-independent TGF-β signaling that drives EMT in pancreatic ductal adenocarcinoma.
    Thakur AK; Nigri J; Lac S; Leca J; Bressy C; Berthezene P; Bartholin L; Chan P; Calvo E; Iovanna JL; Vasseur S; Guillaumond F; Tomasini R
    Cell Death Differ; 2016 Aug; 23(8):1358-70. PubMed ID: 26943320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
    Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
    J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer.
    Mirlekar B; Michaud D; Searcy R; Greene K; Pylayeva-Gupta Y
    Cancer Immunol Res; 2018 Sep; 6(9):1014-1024. PubMed ID: 29980536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
    Quezada SA; Peggs KS; Curran MA; Allison JP
    J Clin Invest; 2006 Jul; 116(7):1935-45. PubMed ID: 16778987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer.
    Tsujikawa T; Crocenzi T; Durham JN; Sugar EA; Wu AA; Onners B; Nauroth JM; Anders RA; Fertig EJ; Laheru DA; Reiss K; Vonderheide RH; Ko AH; Tempero MA; Fisher GA; Considine M; Danilova L; Brockstedt DG; Coussens LM; Jaffee EM; Le DT
    Clin Cancer Res; 2020 Jul; 26(14):3578-3588. PubMed ID: 32273276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer.
    Blair AB; Kim VM; Muth ST; Saung MT; Lokker N; Blouw B; Armstrong TD; Jaffee EM; Tsujikawa T; Coussens LM; He J; Burkhart RA; Wolfgang CL; Zheng L
    Clin Cancer Res; 2019 Sep; 25(17):5351-5363. PubMed ID: 31186314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells.
    Rana M; Kansal R; Chaib M; Teng B; Morrrison M; Hayes DN; Stanfill AG; Shibata D; Carson JA; Makowski L; Glazer ES
    Mol Carcinog; 2022 Jun; 61(6):549-557. PubMed ID: 35319799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.
    Viehl CT; Moore TT; Liyanage UK; Frey DM; Ehlers JP; Eberlein TJ; Goedegebuure PS; Linehan DC
    Ann Surg Oncol; 2006 Sep; 13(9):1252-8. PubMed ID: 16952047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma.
    Heumann T; Judkins C; Li K; Lim SJ; Hoare J; Parkinson R; Cao H; Zhang T; Gai J; Celiker B; Zhu Q; McPhaul T; Durham J; Purtell K; Klein R; Laheru D; De Jesus-Acosta A; Le DT; Narang A; Anders R; Burkhart R; Burns W; Soares K; Wolfgang C; Thompson E; Jaffee E; Wang H; He J; Zheng L
    Nat Commun; 2023 Jun; 14(1):3650. PubMed ID: 37339979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients.
    Oberg HH; Grage-Griebenow E; Adam-Klages S; Jerg E; Peipp M; Kellner C; Petrick D; Gonnermann D; Freitag-Wolf S; Röcken C; Sebens T; Vogel I; Becker T; Ebsen M; Kabelitz D; Wesch D; Sebens S
    Pancreatology; 2016; 16(6):1069-1079. PubMed ID: 27424476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting.
    Lipson EJ; Sharfman WH; Chen S; McMiller TL; Pritchard TS; Salas JT; Sartorius-Mergenthaler S; Freed I; Ravi S; Wang H; Luber B; Sproul JD; Taube JM; Pardoll DM; Topalian SL
    J Transl Med; 2015 Jul; 13():214. PubMed ID: 26143264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel pancreatic cancer vaccines could unleash the army within.
    Springett GM
    Cancer Control; 2014 Jul; 21(3):242-6. PubMed ID: 24955709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.